Friday, February 19, 2021 6:40:13 AM
1. a diagnostic tool, a rapid Covid19 test that not only indicates whether you test positive/negative but also the degree of infection, based on their (patent pending) fluorescent monoclonal antibodies,
2. a nasal spray (patent pending) as an alternative to a Covid19 vaccine,
3. a Covid19 treatment, based on their extracorporeal treatment (US granted patent 9,216,386) using Radio-Frequency to destroy infectious disease pathogens (patent pending). This technology may be used in the near future to eradicate all blood/spinal-fluid borne diseases. Think MS, TBI, Cockayne Syndrome etc
4. a medication to boost the immune system (patent pending), based on a unique combination of nutritional supplements/vitamins in combination with low dose Naltrexone, designed to reduce the symptoms of Covid19
Halberd's unique class of monoclonal antibodies has a Trademark, for commercial use:
https://trademark.trademarkia.com/felderhalberd-monoclonal-antibody-90352046.html
Halberd's partners are:
* Arizona State University ($1,37 million Research Agreement)
https://halberdcorporation.com/wp-content/uploads/2020/09/ASU-K-Fully-Executed.pdf
* GreenBioAZ inc, a start-up from ASU directed by Dr. Qiang Shawn Chen, who is the principal investigator at ASU for Halberd
https://halberdcorporation.com/halberd-collaborates-with-greenbioaz-inc-for-the-development-of-its-patent-pending-radio-frequency-technology-to-eliminate-disease-pathogens/
* Ference & Associates, to handle all intellectual property matters. Halberd is a healthcare technology company and safeguarding its IP is of incredible value
https://ferencelaw.com/about/stanley-ference/
Key personnel or consultants:
- Dr. Mitchell S. Felder, senior consultant, holds all (provisional 7) patents (2) through his MARV Enterprises inc, all (provisional) patents are uniquely licensed to Halberd Corp,
https://health.usnews.com/doctors/mitchell-felder-261173
- Dr. Patricio Reyes, Head Neurology Dept at Carl T. Hayden VA Hospital in Phoenix, AZ, specialist Traumatic Brain Injury and Alzheimer disease, is liaison officer for ASU,
https://biaaz.org/event/covid-19-update-02-11/
- Dr. Qiang Shawn Chen, Professor and Senior Researcher at ASU's Biodesign Insitute, dedicated to a 2 year research agreement with Halberd, CEO of GreenBioAZ inc (doing preclinical testing)
https://biodesign.asu.edu/qiang-shawn-chen
- Mr. William A. Hartman, CEO Halberd Corp, holds 90,9% of voting rights
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM